Oncobiologics (OTLK) – Investment Analysts’ Recent Ratings Changes

by · The Cerbat Gem

A number of research firms have changed their ratings and price targets for Oncobiologics (NASDAQ: OTLK):

  • 8/1/2026 – Oncobiologics was upgraded by Wall Street Zen from “sell” to “hold”.
  • 7/28/2026 – Oncobiologics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
  • 7/27/2026 – Oncobiologics had its price target raised by HC Wainwright to $1.60. They now have a “neutral” rating on the stock.
  • 7/27/2026 – Oncobiologics was upgraded by BTIG Research from “neutral” to “buy”. They now have a $4.00 price target on the stock.
  • 7/18/2026 – Oncobiologics was downgraded by Wall Street Zen from “hold” to “sell”.
  • 6/24/2026 – Oncobiologics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
  • 6/20/2026 – Oncobiologics was upgraded by Wall Street Zen from “sell” to “hold”.

Insider Buying and Selling at Oncobiologics

In other news, Director Faisal Ghiath Sukhtian acquired 95,398 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were purchased at an average cost of $1.05 per share, for a total transaction of $100,167.90. Following the transaction, the director directly owned 220,972 shares of the company’s stock, valued at approximately $232,020.60. This trade represents a 75.97% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ghiath M. Sukhtian bought 8,539,709 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were purchased at an average price of $0.59 per share, for a total transaction of $5,038,428.31. Following the purchase, the director owned 22,092,068 shares in the company, valued at $13,034,320.12. This represents a 63.01% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 8,664,107 shares of company stock worth $5,162,666 over the last 90 days. Insiders own 1.80% of the company’s stock.

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.

Featured Stories